Clinical trial · Interventional
PET/MRI in Endometrial Cancer
Diagnostic Performance of PET/MRI Versus Standard of Care Imaging (PET/CT and/or CT and/or PET) in Preoperative Women With Presumed Early-stage High Grade Endometrial Carcinoma
NCT05390021CI-TRIAL-00075582withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Unable to enroll patients to study
Summary
Brief summary (as posted)
This study is investigating if positron emission tomography (PET)/Magnetic resonance imaging (MRI) is more effective than the currently used imaging modalities (computed tomography \[CT\], or PET/CT) for high-risk endometrial cancer. The name of the intervention involved in this study is: Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI)
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cytoreductive Surgery | — | UNRESOLVED | — |
| Endometrial Mixed Cell Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Endometrial Undifferentiated Carcinoma | Endometrial Undifferentiated Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Grade 3 Endometrial Endometrioid Adenocarcinoma | — | UNRESOLVED | — |
| High Grade Serous Carcinoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- PET/MRI IN ENDOMETRIAL CANCER
- description
- PET/MRI in one study visit of approximately four hours
- interventionNames
- Combination Product: PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent
Primary outcomes (2)
- measure
- Percentage of patients with a metastatic lesion noted on PET/MRI that have a true malignancy noted on surgical pathology of that lesion
- timeFrame
- Baseline
- description
- Sensitivity of PET/MRI to detect metastatic lesions
- measure
- Percentage of patients without any metastatic lesion noted on PET/MRI that do not have malignancy noted on surgical pathology
- timeFrame
- Baseline
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Women aged 18-85 years old with an endometrial biopsy-confirmed diagnosis of either grade 3 endometrioid, serous, carcinosarcoma, undifferentiated or mixed cell carcinoma * Must have presumed stage I disease, i.e., no symptoms suggesting disease outside of the uterus (weight loss, early satiety, bloating, changes in bowel movement, etc.) * Planning to undergo cytoreductive surgery with a Gynecologic oncologist employed by Massachusetts General Hospital * No previous history of chronic severe renal insufficiency and a glomerular filtration rate of \>30 mL/min/1.73m2. If the patient has a history of acute renal failure but their GFR as recovered to above 30, Exclusion Criteria: * Weight greater than 300lbs (the PET/MRI table weight limit) or BMI \> 33 * Subjects less than 18 years of age or greater than 85 years of age * Has Electrical implants, such as cardiac pacemakers or perfusion pumps * Has Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, prosthetic heart valves that are not compatible with the gradient maps of our scanners, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, or steel implants not compatible with a 3 Tesla MR. * Is actively anticipating being pregnant or breastfeeding (a negative STAT quantitative serum hCG pregnancy test is required on the day of the scan before the subject can participate) * Suffers from claustrophobia * If research-related radiation exposure exceeds current Radiology Department guidelines (i.e., 50 mSv in the prior 12 months) * Is unable to lie comfortably on a bed inside the PET/MRI bore as assessed by physical examination and medical history (e.g., back pain, arthritis) * Subject is under the direct professional supervision of the principal investigator * A history of chronic severe renal insufficiency (glomerular filtration rate \<30 mL/min/1.73m2) * Perioperative liver transplantation period
References
Publications (0)
Data not yet available
No reference posted for this study.